| Document |
Document Title |
|
WO/2018/033719A1 |
The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, s...
|
|
WO/2018/028494A1 |
A gemcitabine ProTide hypoxic-activated prodrug and a use thereof in the preparation of a medicament for treating tumors. The general structural formula thereof is formula (A), wherein: one of R1 and R2 is a hypoxic-activated group of -C...
|
|
WO/2018/031818A2 |
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.
|
|
WO/2018/024265A1 |
Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula (I), where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro...
|
|
WO/2018/023205A1 |
A purification method for nicotinamide mononucleotide, relating to a method for purifying an NMN crude product obtained via a biocatalysis method. The purpose of the present method is to solve the problems in existing NMN purification me...
|
|
WO/2018/019748A1 |
The invention relates to a compound of formula (I) wherein R2 and R4 are joined and together form a group, such a -CH2O-. The compound of formula (I) can be used in the manufacture of 5'S-LNA oligonucleotides as antisense drugs.
|
|
WO/2018/019188A1 |
Provided are a crystal form A of a nucleoside phosphoramidate prodrug as shown in formula I and a preparation method therefor. The crystal form A at least has an X-ray powder diffraction (XRPD) pattern with peaks at the 2θ angles of 6.9...
|
|
WO/2018/015821A1 |
The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-f...
|
|
WO/2018/014111A1 |
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...
|
|
WO/2018/011094A1 |
The present invention relates to a compound of the general formula (1), wherein the pyranose ring is alpha-D-galactopyranose, A is selected from (2), and (3). The compound of formula (1) is suitable for use in a method for treating a dis...
|
|
WO/2018/010965A1 |
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...
|
|
WO/2018/011093A1 |
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal...
|
|
WO/2018/013937A1 |
Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in ne...
|
|
WO/2018/008647A1 |
The present invention provides a method for detecting fucose analogue and sugar. The present invention provides, for example, a compound represented by general formula (I) or a salt thereof: (I) {In the formula, L is -(CH2)n- and n is an...
|
|
WO/2018/009623A1 |
A compound or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to a virus of the Paramyxoviridae or Orthomyxoviridae family, or other disorders, in particular respiratory sync...
|
|
WO/2018/002739A1 |
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, form...
|
|
WO/2018/001393A1 |
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of ...
|
|
WO/2017/223020A1 |
The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relat...
|
|
WO/2017/219510A1 |
A quinoid chalcone c-glycoside dimer compound having an anti-tumor activity and an anti-inflammatory activity and a method for preparing same. The compound is a quinoid chalcone c-glycoside dimer compound separated from Carthamus tinctor...
|
|
WO/2017/221083A1 |
The compositions and compounds of formula I which includes ribavirin conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmac...
|
|
WO/2017/223421A1 |
Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives o...
|
|
WO/2017/221929A1 |
The present invention pertains to a method for synthesizing a ribonucleic acid H-phosphonate monomer, and a method for performing oligonucleotide synthesis in which said monomer is used. The present invention pertains to a method for man...
|
|
WO/2017/223012A1 |
The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates...
|
|
WO/2017/223474A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2017/223024A1 |
The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present inve...
|
|
WO/2017/218802A1 |
The disclosure is directed to compounds of Formula (I) and Formula (II). Methods of their use and preparation is other described.
|
|
WO/2017/218580A1 |
The present application is directed to methods of making a pharmaceutically acceptable salt of nicotinamide riboside and related compounds by alkylating nicotinamide with a 1-chloro-D-ribofuranose derivative. The present invention relate...
|
|
WO/2017/214112A1 |
Described are 5'-cyclo-phosphonate modified nucleotides, and oligonucleotides, such as interference (RNAi) agents, containing 5'-cyclo-phosphonate modified nucleotides. The RNAi agents having either double-stranded or single-stranded oli...
|
|
WO/2017/207986A1 |
This invention relates to derivatives of cladribine of Formula (I). The compounds are phosphoramidate derivatives in which the phosphoramidate moiety is situated on the 3'-hydroxyl group of cladribine. The invention also relates to pharm...
|
|
WO/2017/210611A1 |
Described herein are bisphosphonate quinolone conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein...
|
|
WO/2017/207989A1 |
The present invention relates to chemical compounds of formula (I) as defined in the amended claims, their preparation and their use in the treatment of cancer.
|
|
WO/2017/207754A1 |
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
|
|
WO/2017/203395A1 |
The present invention relates to novel crystalline forms of L-alanine,N-[(S)-[[(lR)-2-(6- amino-9H-purin-9-yl)-1methylethoxy]methyl]phenoxyphosphinyl]
-1-methylethyl ester, (2E)- 2-butenedioate or Tenofovir Alafenamide hemi fumarate(I). ...
|
|
WO/2017/204583A1 |
The present invention relates to a composition for inducing transformation of non-neuronal cells into induced neural stem cells, a kit, for inducing transformation of non-neuronal cells into induced neural stem cells, comprising the comp...
|
|
WO/2017/205336A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of thereof in the sequencing a nucleic acid.
|
|
WO/2017/198775A1 |
The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates t...
|
|
WO/2017/199028A1 |
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...
|
|
WO/2017/194498A1 |
The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers and methods of synthesis of stereodefined oligonucleotides. Herein are disclosed solvent compositions...
|
|
WO/2017/196697A1 |
This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
|
|
WO/2017/190715A1 |
The invention relates to a preparation method of an amorphous form of sofosbuvir of formula I, (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2
H)-yl)-4- fluoro-3-hydroxy-4-memyltetrahydrofuran-2-yl)methoxy)-(ph...
|
|
WO/2017/189978A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2017/185549A1 |
Provided is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP, and ribose react under the catalytic effects of nicotinamide phosphoribosyltransferase, phosphoribose pyrophosphokinase, and ribokinase so a...
|
|
WO/2017/184885A1 |
Compositions are provided including nicotinic acid riboside ("NAR"), and derivatives thereof including l -(2',3 ',5'-triacetyl-beta-D-ribofuranosyl)-nicotinic acid ("NAR triacetate" or "NARTA"); or derivatives of a reduced form of nicoti...
|
|
WO/2017/183217A1 |
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...
|
|
WO/2017/183215A1 |
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...
|
|
WO/2017/184668A1 |
Provided are methods for treating Flaviviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositi...
|
|
WO/2017/174322A1 |
The present invention relates to the field of powders, particularly food powders, and to the avoidance of caking in such powders by using compositions comprising dehydrated or partially dehydrated disodium inosine monophosphate salts.
|
|
WO/2017/176677A1 |
This invention provides nucleotide analogues each of which comprises a tag comprising one or more Forster resonance energy transfer (FRET) acceptor fluorophores, a nucleotide polymerase having one or more FRET donor fluorophores, and met...
|
|
WO/2017/170348A1 |
Provided are methods, uses, and compositions for treating acute myeloid leukemia which includes therapeutically effective combinations of 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin
-1-yl]phenyl}amino)-5-(tetrahydro-2H-p...
|
|
WO/2017/163186A1 |
The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these...
|
